New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
11:05 EDTRGP, DMND, JE, BKD, CMLP, JNS, ALIM, IRWD, WYN, TPHHigh option volume stocks
High option volume stocks: ALIM BKD TPH JNS JE WYN CMLP DMND IRWD RGP
News For ALIM;BKD;TPH;JNS;JE;WYN;CMLP;DMND;IRWD;RGP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
11:55 EDTWYNStarwood reaching out to possible bidders for company, Reuters reports
Subscribe for More Information
July 28, 2015
06:36 EDTWYNWyndham raises FY15 adjusted EPS view to $4.88-$5.03 from $4.81-$4.96
Subscribe for More Information
06:35 EDTWYNWyndham reports Q2 adjusted EPS $1.32, consensus $1.26
Subscribe for More Information
July 23, 2015
07:01 EDTJNSJanus Capital reports Q2 EPS 23c, consensus 24c
Subscribe for More Information
July 22, 2015
07:38 EDTIRWDIronwood announces data from Phase I IW-1973 study
Ironwood Pharmaceuticals announced top-line data from a Phase I study of IW-1973, its lead investigational soluble guanylate cyclase stimulator. In the study, IW-1973 demonstrated cardiovascular pharmacodynamic effects, extensive tissue distribution, proof of mechanism for sGC stimulation, and a dose range that was well tolerated in healthy volunteers. The totality of clinical and preclinical data generated to date strongly support continued development of IW-1973 as a potential once-daily oral therapy. Ironwood intends to initiate a Phase Ib multiple ascending dose study of IW-1973 in the fourth quarter of 2015. This study will inform the selection of doses and priority indications for the Phase II program, which will focus on areas with the highest unmet need and optimal path to market. Ironwood intends to initiate at least two Phase II proof of concept studies for IW-1973 in 2016. The randomized, double-blind, placebo-controlled, single ascending dose Phase I study enrolled 46 healthy volunteers. Participants were randomized 3:1 to receive a single dose of IW-1973 or placebo administered via an oral capsule. Top-line clinical data were consistent with preclinical findings and included cardiovascular pharmacodynamic effects, dose-proportional pharmacokinetics, biomarker-based confirmation of target engagement, and evidence of extensive distribution to tissues. No serious adverse events were reported. Reported adverse events were consistent with the mechanism of action. Data from clinical and preclinical studies of IW-1973 are expected to be presented at a future medical conference.
July 21, 2015
07:37 EDTALIMAlimera Sciences signs exclusive agreement for distribution of Iluvien in Canada
Alimera Sciences announced that it has signed an exclusive agreement with Knight Therapeutics, a leading Canadian specialty pharmaceutical company, for the distribution in Canada of ILUVIEN, Alimera's sustained release intravitreal implant for the treatment of diabetic macular edema. Under the terms of this agreement, Knight will also handle all regulatory and commercial activities for ILUVIEN in Canada. ILUVIEN currently is not approved for sale in Canada.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use